• Explore /
  • Poster
  • / A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.

A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.

Abstract Poster

Authors

null

Montaser F. Shaheen

University of Texas Health Science Ctr, San Antonio, TX

Montaser F. Shaheen , Jennifer Margaret Segar , Bartosz Chmielowski , Joseph J. Drabick , Meredith McKean , James A. Reeves Jr., Christos Stelios Karapetis , Marlana M. Orloff , Anthony W. Tolcher , J. Thaddeus Thaddeus Beck , Brian Gastman , Asit De , Ben Paudyal , Robert E Winkler , Mingyu Li , Mohammad Ahmad , Dajun Yang , Yifan Zhai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03611868

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9559)

DOI

10.1200/JCO.2023.41.16_suppl.9559

Abstract #

9559

Poster Bd #

322

Abstract Disclosures

Similar Posters

First Author: Meredith McKean

First Author: Anthony W. Tolcher

First Author: Samuel J Klempner

First Author: Justine Yang Bruce